Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Chiesi Global Rare Diseases

Rare Disease news

Rare Disease Video Recap—March 12, 2026

This biweekly Rare diseases video recap highlights regulatory decisions, orphan…

Rare Disease news

Rare Diseases Today—March 12, 2026

This week’s Rare Diseases update highlights regulatory approvals, gene therapy…

Rare Disease news

Rare Disease Video Recap—February 12, 2026

This biweekly Rare Disease Video Recap covers regulatory actions, late-stage…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: AstraZeneca’s tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Respiratory Today—March 27, 2026
Vaccines Today—March 27, 2026

Tags

AAV-based gene therapies adaptive design American Academy of Pediatrics American Society of Clinical Oncology Autoimmune disease therapies cancer care Cancer drug development cancer vaccines CervicalCancer Clearmind Medicine clinicaltrials competitive advantage CVC Cytokine release syndrome datasecurity digital health innovation digital pill drug development Echocardiography monitoring EGFR-mutated non-small cell lung cancer fair pricing FDA gene therapy approvals FDA neuroscience approvals google ventures Healthcare Policy HeartFlow hepatitis D Izalontamab Brengitecan mental health Minimally invasive surgery Nipocalimab NMDA Obesity market trends Pain patient centricity Rare blood disorders Rare disease drug pipeline Sapien M3 surgical robotics Tecvayli UKHSA US health crisis Venous thromboembolism VOICE ASSISTANT Women’s health market trends

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: AstraZeneca’s tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Respiratory Today—March 27, 2026
Vaccines Today—March 27, 2026

TAGS

AAV-based gene therapies adaptive design American Academy of Pediatrics American Society of Clinical Oncology Autoimmune disease therapies cancer care Cancer drug development cancer vaccines CervicalCancer Clearmind Medicine clinicaltrials competitive advantage CVC Cytokine release syndrome datasecurity digital health innovation digital pill drug development Echocardiography monitoring EGFR-mutated non-small cell lung cancer fair pricing FDA gene therapy approvals FDA neuroscience approvals google ventures Healthcare Policy HeartFlow hepatitis D Izalontamab Brengitecan mental health Minimally invasive surgery Nipocalimab NMDA Obesity market trends Pain patient centricity Rare blood disorders Rare disease drug pipeline Sapien M3 surgical robotics Tecvayli UKHSA US health crisis Venous thromboembolism VOICE ASSISTANT Women’s health market trends

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy